Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

  • Sort by:
  • Browse by:
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 50 of 96 from CROI 2016
Plenary
Progress in Gene Therapy for HIV Cure
Paula M. Cannon
University of Southern California, Los Angeles, CA, United States
from CROI 2016 on February 24, 2016 8:30 AM-9:00 AM
Plenary
HIV in Transgender Populations: Charted and Uncharted Waters
Tonia C. Poteat
Johns Hopkins University, Baltimore, MD, United States
from CROI 2016 on February 24, 2016 9:00 AM-9:30 AM
Oral Abstract: Drugs: From Discovery to Challenges in Clinical Use
Pharmacologic Measures of Adherence and Relationship to Drug Response
Peter L Anderson
University of Colorado, Denver, CO, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Drugs: From Discovery to Challenges in Clinical Use
HIV-1 Combinectin BMS-986197: A Long-Acting Inhibitor With Multiple Modes of Action
Mark Krystal
Bristol-Myers Squibb, Wallingford, CT, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Drugs: From Discovery to Challenges in Clinical Use
Long-Acting Oral and Parenteral Dosing of MK-8591 for HIV Treatment or Prophylaxis
Jay Grobler
Merck & Co, West Point, PA, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Drugs: From Discovery to Challenges in Clinical Use
Lower Ribavirin Exposures in HIV+ Patients That Relapsed to Acute HCV Treatment
Christine E. MacBrayne
University of Colorado, Denver, CO, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Drugs: From Discovery to Challenges in Clinical Use
Drug Interaction Studies Between Sofosbuvir/Velpatasvir and Boosted HIV ARV Regimens
Erik Mogalian
Gilead Sciences, Foster City, CA, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Drugs: From Discovery to Challenges in Clinical Use
EFV Reduced PK of Piperaquine for Malaria Prevention in HIV+ Ugandan Pregnant Women
Richard Kajubi
Makerere University, Kampala, Uganda
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Drugs: From Discovery to Challenges in Clinical Use
Concentrations of TFV and TFVdp in Female Mucosal Tissues After a Single Dose of TAF
Katy L. Garrett
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Expanding the Toolbox for Prevention
HPTN 069/ACTG 5305: Phase II Study of Maraviroc-Based Regimens for HIV PrEP in MSM
Roy Gulick
Weill Cornell Medical College, New York, NY, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Expanding the Toolbox for Prevention
PrEP Impact on T-Cell Activation and Explant Infection: HPTN 069/ACTG 5305 Substudy
Ian McGowan
University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Expanding the Toolbox for Prevention
Cabotegravir Long-Acting Injection Protects Macaques Against Intravenous Challenge
Chasity D. Andrews
Aaron Diamond AIDS Research Center, New York, NY, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Expanding the Toolbox for Prevention
ÉCLAIR: Phase 2A Safety and PK Study of Cabotegravir LA in HIV-Uninfected Men
Martin Markowitz
Aaron Diamond AIDS Research Center, New York, NY, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Expanding the Toolbox for Prevention
Chemoprophylaxis With Oral FTC/TAF Protects Macaques From Rectal SHIV Infection
Gerardo Garcia-Lerma
Centers for Disease Control and Prevention, Atlanta, GA, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Expanding the Toolbox for Prevention
MTN-017: Rectal Phase 2 Extended Safety and Acceptability Study of 1% Tenofovir Gel
Ross Cranston
University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Expanding the Toolbox for Prevention
A Phase III Trial of the Dapivirine Vaginal Ring for HIV-1 Prevention in Women
Jared M. Baeten
University of Washington, Seattle, WA, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Expanding the Toolbox for Prevention
Safety and Efficacy of Dapivirine Vaginal Ring for HIV-1 Prevention in African Women
Annalene Nel
International Partnership for Microbicides, Paarl, South Africa
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Getting to 90-90-90
Oral Abstract Moderator
Marco Vitoria
World Health Organization, Geneva, Switzerland
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Getting to 90-90-90
Botswana Is Close to Meeting UNAIDS 2020 Goals of 90-90-90 Coverage
Tendani Gaolathe
Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Getting to 90-90-90
Streamlining Antiretroviral Therapy Uptake: A Stepped-Wedge Cluster Randomized Trial
Gideon Amanyire
Makerere University College of Health Sciences, Kampala, Uganda
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Getting to 90-90-90
A Randomized Trial to Accelerate HIV Care and ART Initiation Following HIV Diagnosis
Christopher Hoffmann
Johns Hopkins University School of Medicine, Baltimore, MD, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Getting to 90-90-90
Towards the Second UNAIDS Target: Population-Level ART Coverage in HPTN 071 (PopART)
Sarah J. Fidler
Imperial College London, London, United Kingdom
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Getting to 90-90-90
Optimising South Africa's HIV Response: Results of the HIV and TB Investment Case
Calvin Chiu
University of the Witwatersrand, Johannesburg, South Africa
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Getting to 90-90-90
Virologic Efficacy of ART Begun at High CD4+ Counts via Streamlined Care in East Africa
Dalsone Kwarisiima
Makerere University-University of California San Francisco Research Collaboration, Kampala, Uganda
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Getting to 90-90-90
HIV Mortality by Care Cascade Stage and Implications for Universal ART Eligibility
Jeffrey W. Eaton
Imperial College London, London, United Kingdom
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Getting to 90-90-90
Trends in ART Discontinuation by Age in Malawi, 2004-2014
Catrina Andrea Mugglin
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Pushing Frontiers of Adaptive Immunity
An Infant bNAb With Low Somatic Hypermutation Contributes to Polyclonal Breadth
Cassandra Simonich
Fred Hutchinson Cancer Research Center, Seattle, WA, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Pushing Frontiers of Adaptive Immunity
Virus, Host, and Disease Factors Govern HIV-1 Broadly Neutralizing Antibody Induction
Alexandra Trkola
University of Zurich, Zurich, Switzerland
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Pushing Frontiers of Adaptive Immunity
Clinical Safety and Pharmacokinetics of IV and SC VRC01, a Broadly Neutralizing mAb
Kenneth H. Mayer
The Fenway Institute, Fenway Health, Boston, MA, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Pushing Frontiers of Adaptive Immunity
Neutrophil Functions Induced by Gp-120 Specific IgA and IgG; Clues for Immunotherapy
Magdalena Sips
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Pushing Frontiers of Adaptive Immunity
Potency and Kinetics of Autologous HIV-1 Neutralizing Antibody Responses During ATI
Brenda Salantes
University of Pennsylvania, Philadelphia, PA, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Pushing Frontiers of Adaptive Immunity
PD-1 Blockade as an Adjunct Therapy to ART and Potential to Destabilize SIV Reservoir
Geetha Mylvaganam
Emory University, Atlanta, GA, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Pushing Frontiers of Adaptive Immunity
Follicular CTL Accumulate in SIV-Infected Lymph Nodes Due to Immune Activation
Costantinos Petrovas
National Institutes of Health, Bethesda, MD, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Pushing Frontiers of Adaptive Immunity
Repeated TLR7 Agonist Treatment of SIV+ Monkeys on ART Can Lead to Viral Remission
James B. Whitney
Beth Israel Deaconess Medical Center, Boston, MA, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Reservoirs, Relapse, and Remission
Investigating the Mechanisms that Control HIV Transcription and Latency In Vivo
Steven A. Yukl
San Francisco VA Medical Center, San Francisco, CA, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Reservoirs, Relapse, and Remission
Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation
Mohamed Abdel-Mohsen
Blood Systems Research Institute, San Francisco, CA, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Reservoirs, Relapse, and Remission
PD-1+ and Tfh Cells Represent the Major Source of HIV-1 Replication-Competent Virus
Riddhima Banga
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Reservoirs, Relapse, and Remission
Rapid Accumulation of Defective Proviruses Complicates HIV-1 Reservoir Measurements
Katherine M. Bruner
Johns Hopkins University School of Medicine, Baltimore, MD, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Reservoirs, Relapse, and Remission
Clones of SIV-Infected Cells Are Present in Spleen and Lymph Nodes in Rhesus Macaques
Stephen H. Hughes
National Cancer Institute, Frederick, MD, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Reservoirs, Relapse, and Remission
ART Reduces Cellular HIV RNA but Not the Fraction of Proviruses Transcribing RNA
Mary F. Kearney
National Cancer Institute, Frederick, MD, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Reservoirs, Relapse, and Remission
Restricted HIV-1 Diversity and Clonal Expansion Following Cytoreductive Chemotherapy
Emily Hanhauser
University of California San Francisco, San Francisco, CA, United States
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Oral Abstract: Reservoirs, Relapse, and Remission
Virological Remission After ART Interruption in African HIV-1 Seroconverters
Morgane Gossez
University of Oxford, Oxford, United Kingdom
from CROI 2016 on February 24, 2016 10:00 AM-12:00 PM
Wednesday Press Conference
Discussion of Oral Abstract Session 10 – Getting to 90-90-90 and Symposium Session 5 – Reaching 90-90-90 and Beyond: Challenges and Innovations
Chair
Diane Havlir
University of California, San Francisco, CA, United States
OA10: Botswana Is Close to Meeting UNAIDS 2020 Goals of 90-90-90 Coverage
Tendani Gaolathe
Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
OA10: Streamlining Antiretroviral Therapy Uptake: A Stepped-Wedge Cluster Randomized Trial
Gideon Amanyire
Makerere University College of Health Sciences, Kampala, Uganda
OA10: HIV Mortality by Care Cascade Stage and Implications for Universal ART Eligibility
Jeffrey Eaton
Imperial College London, London, United Kingdom
SS5: Missing But in Action: Where Are the Men?
Helen Ayles
London School of Hygiene & Tropical Medicine, London, United Kingdom
SS5: Innovations in Antiretroviral Therapy Delivery
Anna Grimsrud
International AIDS Society, Cape Town, South Africa
from CROI 2016 on February 24, 2016 12:30 PM-1:30 PM
Wednesday Press Conference
Discussion of Oral Abstract Session 9 – Expanding the Toolbox for Prevention and Themed Discussion Session 12 – It's Complicated: Renal Function and STIs in PrEP Users and Poster Abstract Session 3 – Predictors of PrEP Coverage and Uptake
Chair
Sharon L. Hillier
University of Pittsburgh School of Medicine, Magee-Womens Hospital, PA, United States
OA9: ÉCLAIR: Phase 2A Safety and PK Study of Cabotegravir LA in HIV Uninfected Men
Martin Markowitz
Aaron Diamond AIDS Research Center, New York, NY, United States
TD12: Higher Cumulative TFV/FTC Levels in PrEP Associated With Decline in Renal Function
Monica Gandhi
University of California San Francisco, San Francisco, CA, United States
TD12: Changes in Renal Function Associated With TDF/FTC PrEP Use in the US Demo Project
Albert Y. Liu
San Francisco Dept of Public Health, San Francisco, CA, United States
TD12: STI Data From Community-Based PrEP Implementation Suggest Changes to CDC Guidelines
Sarit A. Golub
Hunter College, City University of New York, NY, United States
PAS3: HPTN 073: PrEP Uptake and Use by Black Men Who Have Sex With Men in 3 US Cities
Darrell P. Wheeler
State University of New York at Albany, Albany, NY, United States
from CROI 2016 on February 24, 2016 12:30 PM-1:30 PM
Themed Discussion: Cryptococcal Disease: Detection and Complications
Maximizing Detection and Improving Outcomes of Cryptococcosis in Rural Tanzania
Emilio Letang
Swiss Tropical Institute of Public Health, Basel, Switzerland
from CROI 2016 on February 24, 2016 1:45 PM-2:45 PM
Themed Discussion: Cryptococcal Disease: Detection and Complications
Evaluation of Provider-Initiated Cryptococcal Antigen Screening, South Africa
Nicky Longley
St George's University of London, London, United Kingdom
from CROI 2016 on February 24, 2016 1:45 PM-2:45 PM
Themed Discussion: Cryptococcal Disease: Detection and Complications
Immunologic Discrimination of Cryptococcal IRIS From Culture-Positive Relapse
David R. Boulware
University of Minnesota, Minneapolis, MN, United States
from CROI 2016 on February 24, 2016 1:45 PM-2:45 PM
Themed Discussion: Cryptococcal Disease: Detection and Complications
Neurocognitive Function in HIV-Infected Persons With Cryptococcal Antigenemia
Martha P. Montgomery
University of Minnesota, Minneapolis, MN, United States
from CROI 2016 on February 24, 2016 1:45 PM-2:45 PM
Themed Discussion: Cryptococcal Disease: Detection and Complications
Questions and Answers
from CROI 2016 on February 24, 2016 1:45 PM-2:45 PM
Themed Discussion: HIV and Microbiomes
Themed Discussion Leader
Nichole Klatt
University of Washington, Seattle, WA, United States
from CROI 2016 on February 24, 2016 1:45 PM-2:45 PM
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 50 of 96 from CROI 2016